Drugs / doxecitine
doxecitine
also known as
Deoxycytidine · 2'-deoxycytidine · dCyt · Doxecitine component of mt-1621 2'-deoxycytidine · MT1621 (dC)
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Kygevvi | — | 2026-03-26 | europa.eu ↗ |
| Approved | US (FDA) | KYGEVVI | — | 2025-11-03 | fda.gov ↗ |
Trials 8
Press releases naming this drug 4 releases
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | doxecitine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06590493 ↗ |
| Known as | 2'-deoxycytidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL66115 ↗ |
| Known as | dCyt | “open label deoxythymidine (dThd) and deoxycytidine (dCyt), which are nucleotide precursors” NCT03639701 ↗ |
| Known as | Deoxycytidine | “Treatment of TK2 Deficiency With Thymidine and Deoxycytidine” NCT03639701 ↗ |
| Known as | Doxecitine component of mt-1621 2'-deoxycytidine | ChEMBL registry synonym — accepted as the source's own label CHEMBL66115 ↗ |
| Known as | MT1621 (dC) | ChEMBL registry synonym — accepted as the source's own label CHEMBL66115 ↗ |
| Modality | Small molecule | “Combination Pyrimidine Nucleosides” NCT03845712 ↗ |
| Route | Intravenous | “Patients receive deoxycytidine IV over 120 hours” NCT00002818 ↗ |